BioOutsource to open biosimilar centre of excellence in Glasgow
Biosimilars analysis capacity to double with addition of new facility
BioOutsource, a provider of biologics contract testing and biosimilar characterisation for the biopharmaceutical industry, is to open a new Biosimilar Centre of Excellence in Glasgow, Scotland.
The new facility, located on the West of Scotland Science Park in Glasgow adjacent to the firm's existing premises, will double the company’s capacity for the analysis of biosimilar monoclonal antibodies.
The new operation will consist of approximately 40 laboratory and R&D scientists and will create around 20 new jobs.
BioOutsource CEO, Gerry MacKay, said: 'The global biosimilar market is predicted to more than double in size to US$19bn by 2018. The increasing demand for our biosimilars services and the addition of several new clients has made this a necessary investment for 2014, as our revenues in this market have quadrupled in the last 18 months.'
MacKay added: 'We are committed to providing our clients with excellent levels of service and technical support. In 2013 we increased our headcount by 30% as we added new services to our portfolio and we anticipate repeating this expansion in the first quarter of this year. We have now worked with no fewer than 30 global biosimilar companies who use our range of off-the-shelf assays for the comparability, stability and lot release testing of their biosimilars.'
